• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较多黏菌素 B 和黏菌素对多重耐药革兰氏阴性菌的抗菌活性。

Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.

机构信息

a Department of Medical Microbiology, Faculty of Medicine, Beykoz Institute of Life Sciences and Biotechnology, Bezmialem Vakif University , Istanbul , Turkey.

出版信息

Infect Dis (Lond). 2019 Sep;51(9):676-682. doi: 10.1080/23744235.2019.1640386. Epub 2019 Jul 12.

DOI:10.1080/23744235.2019.1640386
PMID:31298061
Abstract

Polymyxin B and colistin have similar structures except for one amino acid. Usually, physicians choose either polymyxin B or colistin for treatment of infections caused by multidrug-resistant (MDR) organisms. The preference is based on previous experience. Not much data are found in the literature comparing the two drugs against the same microorganisms. In this study, we compared antimicrobial activities of the two polymyxins against a panel of highly resistant and susceptible microorganisms. Eighty-nine clinical isolates (27 , 31 and 31 ) were tested in broth microdilution assays. Time-kill curve experiments were carried out on selected isolates. Significantly lower MICs for polymyxin B than for colistin were found against all species tested including ( .02), ( < .001) and ( < .01). The low MICs caused a change in categorical interpretations of only two and two . Similar results were obtained in time-kill curve experiments with both susceptible and resistant clinical isolates. Significantly lower MICs were found for polymyxin B against three of the most critical MDR species. Even though differences in categorical interpretations were not striking, lower MICs might be a critical consideration in clinical management of select cases where the concentration of these toxic antibiotics matters because of underlying co-morbidities. These results provide support to previous suggestions that re-consideration of breakpoint interpretations for polymyxins might be needed.

摘要

多黏菌素 B 和黏菌素的结构相似,仅差一个氨基酸。通常,医生会根据以往经验选择多黏菌素 B 或黏菌素来治疗多重耐药(MDR)病原体引起的感染。在本研究中,我们比较了两种多黏菌素对一组高度耐药和敏感微生物的抗菌活性。89 株临床分离株(27 株、31 株和 31 株)在肉汤微量稀释法中进行了检测。对选定的分离株进行了时间杀伤曲线实验。与所有测试的物种相比,多黏菌素 B 的 MIC 值均显著低于黏菌素,包括 (.02)、 ( < .001)和 ( <.01)。仅对两个 和两个 进行了分类解释的变化。在时间杀伤曲线实验中,对敏感和耐药的临床分离株也得到了相似的结果。多黏菌素 B 对三种最关键的 MDR 物种的 MIC 值显著降低。尽管分类解释的差异并不显著,但对于某些情况下,由于潜在的合并症,这些毒性抗生素的浓度很重要,因此较低的 MIC 值可能是临床管理的一个关键考虑因素。这些结果为先前的建议提供了支持,即可能需要重新考虑多黏菌素的断点解释。

相似文献

1
Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.比较多黏菌素 B 和黏菌素对多重耐药革兰氏阴性菌的抗菌活性。
Infect Dis (Lond). 2019 Sep;51(9):676-682. doi: 10.1080/23744235.2019.1640386. Epub 2019 Jul 12.
2
A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.全细胞筛选发现与多粘菌素协同作用并具有抗多重耐药菌活性的小分子生物活性物质。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01677-19.
3
[Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].[纸片扩散法、E试验法和肉汤微量稀释法用于测定多重耐药鲍曼不动杆菌分离株对黏菌素、多黏菌素B和替加环素耐药性的比较]
Mikrobiyol Bul. 2010 Apr;44(2):203-10.
4
From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.从乳腺癌到抗菌:利用多粘菌素B与选择性雌激素受体调节剂的新型组合对抗极具耐药性的革兰氏阴性“超级细菌”
Microb Drug Resist. 2017 Jul;23(5):640-650. doi: 10.1089/mdr.2016.0196. Epub 2016 Dec 9.
5
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.多粘菌素作为抗多重耐药革兰氏阴性菌药物的评估。
Int J Antimicrob Agents. 2005 Jan;25(1):11-25. doi: 10.1016/j.ijantimicag.2004.10.001.
6
Performances of the Rapid Polymyxin and Tests for Colistin Susceptibility Testing.快速检测多黏菌素和多黏菌素药敏试验的性能。
Microb Drug Resist. 2019 May;25(4):520-523. doi: 10.1089/mdr.2018.0153. Epub 2018 Dec 1.
7
Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.在纽约市,多粘菌素 B 和新型多粘菌素类似物 CB-182,804 对当代革兰氏阴性病原体的活性。
Microb Drug Resist. 2012 Apr;18(2):132-6. doi: 10.1089/mdr.2011.0163. Epub 2011 Dec 23.
8
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?多粘菌素联合疗法治疗耐多药、广泛耐药和难治性耐药革兰氏阴性菌感染:它是否优于多粘菌素单药治疗?
Expert Rev Anti Infect Ther. 2023 Apr;21(4):387-429. doi: 10.1080/14787210.2023.2184346. Epub 2023 Mar 8.
9
In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.多黏菌素联合用药对多黏菌素耐药鲍曼不动杆菌、铜绿假单胞菌和肺炎克雷伯菌的体外协同作用。
Antimicrob Agents Chemother. 2012 Sep;56(9):4856-61. doi: 10.1128/AAC.05996-11. Epub 2012 Jul 2.
10
Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli.评价新型多黏菌素 B 类似物 SPR206 对临床多重耐药、耐黏菌素和替加环素的革兰氏阴性杆菌的体外活性。
J Antimicrob Chemother. 2020 Sep 1;75(9):2609-2615. doi: 10.1093/jac/dkaa217.

引用本文的文献

1
Prevention of donation-related infections: investigating the use of antibiotics in the decontamination of preservation fluid for organ transplantation.预防与捐赠相关的感染:研究抗生素在器官移植保存液净化中的应用。
Front Cell Infect Microbiol. 2025 Jul 23;15:1572799. doi: 10.3389/fcimb.2025.1572799. eCollection 2025.
2
Nanoformulation of Polymyxin E Through Complex Coacervation: A Pharmacokinetic Analysis.通过复凝聚法制备多粘菌素E纳米制剂:药代动力学分析
Pharmaceutics. 2025 Jan 8;17(1):76. doi: 10.3390/pharmaceutics17010076.
3
Polymyxins: recent advances and challenges.
多粘菌素:最新进展与挑战
Front Pharmacol. 2024 Jun 21;15:1424765. doi: 10.3389/fphar.2024.1424765. eCollection 2024.
4
Synergistic effects of polymyxin and vancomycin combinations on carbapenem- and polymyxin-resistant and their molecular characteristics.黏菌素与万古霉素联合使用对碳青霉烯类和多黏菌素类耐药 和 的协同作用及其分子特征。
Microbiol Spectr. 2023 Dec 12;11(6):e0119923. doi: 10.1128/spectrum.01199-23. Epub 2023 Oct 31.
5
Effects of Aerosol Inhalation Combined with Intravenous Drip of Polymyxin B on Bacterial Clearance, Symptoms Improvement, and Serum Infection Indexes in Patients with Pneumonia Induced by Multidrug-Resistant Gram-Negative Bacteria.雾化吸入联合静脉滴注多黏菌素B对多重耐药革兰阴性菌所致肺炎患者细菌清除、症状改善及血清感染指标的影响
Emerg Med Int. 2022 Aug 28;2022:5244538. doi: 10.1155/2022/5244538. eCollection 2022.
6
Rapid high-resolution detection of colistin resistance in Gram-negative bacteria using flow cytometry: a comparison with broth microdilution, a commercial screening test and WGS.使用流式细胞术快速高分辨率检测革兰氏阴性菌中的多粘菌素耐药性:与肉汤微量稀释法、商业筛选试验和 WGS 的比较。
J Antimicrob Chemother. 2021 Nov 12;76(12):3183-3191. doi: 10.1093/jac/dkab328.
7
[Significance of Lipopolysaccharide Lipid A Gene Mutation of Extensively Drug-resistant on Polymyxin Resistance and Its Influence on Treatment].[广泛耐药菌脂多糖脂质A基因突变对多黏菌素耐药性的意义及其对治疗的影响]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2021 Jan;52(1):124-128. doi: 10.12182/20210160208.